Suppr超能文献

马拉维利隆圭的艾滋病病毒治疗机构中,抗逆转录病毒治疗开始前后的失访情况。

Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilongwe, Malawi.

作者信息

Tweya Hannock, Oboho Ikwo Kitefre, Gugsa Salem T, Phiri Sam, Rambiki Ethel, Banda Rebecca, Mwafilaso Johnbosco, Munthali Chimango, Gupta Sundeep, Bateganya Moses, Maida Alice

机构信息

The International Union Against Tuberculosis and Lung Disease, Paris, France.

Lighthouse Trust, Lilongwe, Malawi.

出版信息

PLoS One. 2018 Jan 26;13(1):e0188488. doi: 10.1371/journal.pone.0188488. eCollection 2018.

Abstract

INTRODUCTION

Although several studies have explored factors associated with loss to follow-up (LTFU) from HIV care, there remains a gap in understanding how these factors vary by setting, volume of patient and patients' demographic and clinical characteristics. We determined rates and factors associated with LTFU in HIV care Lilongwe, Malawi.

METHODS

We conducted a retrospective cohort study of HIV-infected individuals aged 15 years or older at the time of registration for HIV care in 12 ART facilities, between April 2012 and March 2013. HIV-positive individuals who had not started ART (pre-ART patients) were clinically assessed to determine ART eligibility at registration and during clinic follow-up visits. ART-eligible patients were initiated on triple antiretroviral combination. Study data were abstracted from patients' cards, facility ART registers or electronic medical record system from the date of registration for HIV care to a maximum follow-up period of 24 months. Descriptive statistics were undertaken to summarize characteristics of the study patients. Separate univariable and multivariable poisson regression models were used to explore factors associated with LTFU in pre-ART and ART care.

RESULTS

A total of 10,812 HIV-infected individuals registered for HIV care. Of these patients, 1,907 (18%) and 8,905 (82%) enrolled in pre-ART and ART care, respectively. Of the 1,907 pre-ART patients, 490 (26%) subsequently initiated ART and were included in both the pre-ART and ART analyses. The LTFU rates among patients in pre-ART and ART care were 48 and 26 per 100 person-years, respectively. Of the 9,105 ART patients with reasons for starting ART, 2,451 (27%) were initiated on ART because of pregnancy or breastfeeding (Option B+) status. Multivariable analysis showed that being ≥35 years and female were associated with decreased risk of LTFU in the pre-ART and ART phases of HIV care. However, being in WHO clinical stage 3 (adjusted risk ratio (aRR) 1.35, 95% confidence interval (CI): 1.20-1.51) and stage 4 (aRR 1.87, 95% CI: 1.62-2.18), body mass index ≤ 18.4 (aRR 1.24, 95% CI: 1.11-1.39) at ART initiation, poor adherence to clinic appointments (aRR 4.55, 95% CI: 4.16-4.97) and receiving HIV care in rural facilities (aRR 2.32, 95% CI: 1.94-2.87) were associated with increased risk of LTFU among ART patients. Being re-initiated on ART once (aRR 0.20, 95% CI: 0.17-0.22), more than once (aRR 0.06, 95% CI: 0.05-0.07), and being enrolled at a low-volume facility (aRR 0.25, 95% CI: 0.20-0.30) were associated with decreased risk of LTFU from ART care.

CONCLUSION

A sizeable proportion of ART LTFU occurred among women enrolled during pregnancy or breast-feeding. Non- compliance to clinic and receiving ART in a rural facility or high-volume facility were associated with increased risk of LTFU from ART care. Developing effective interventions that target high-risk subgroups and contexts may help reduce LTFU from HIV care.

摘要

引言

尽管多项研究探讨了与艾滋病毒治疗失访相关的因素,但在理解这些因素如何因环境、患者数量以及患者的人口统计学和临床特征而异方面仍存在差距。我们确定了马拉维利隆圭艾滋病毒治疗中失访的发生率及相关因素。

方法

我们对2012年4月至2013年3月期间在12个抗逆转录病毒治疗机构登记接受艾滋病毒治疗时年龄在15岁及以上的艾滋病毒感染者进行了一项回顾性队列研究。未开始抗逆转录病毒治疗的艾滋病毒阳性个体(抗逆转录病毒治疗前患者)在登记时和门诊随访期间进行临床评估以确定是否符合抗逆转录病毒治疗条件。符合抗逆转录病毒治疗条件的患者开始接受三联抗逆转录病毒联合治疗。研究数据从患者卡片、机构抗逆转录病毒治疗登记册或电子病历系统中提取,从艾滋病毒治疗登记之日起最长随访24个月。进行描述性统计以总结研究患者的特征。分别使用单变量和多变量泊松回归模型来探讨抗逆转录病毒治疗前和治疗阶段与失访相关的因素。

结果

共有10812名艾滋病毒感染者登记接受艾滋病毒治疗。其中,1907名(18%)和8905名(82%)分别纳入抗逆转录病毒治疗前和治疗组。在1907名抗逆转录病毒治疗前患者中,490名(26%)随后开始接受抗逆转录病毒治疗,并被纳入抗逆转录病毒治疗前和治疗分析。抗逆转录病毒治疗前和治疗组患者的失访率分别为每100人年48例和26例。在9105名有开始抗逆转录病毒治疗原因的抗逆转录病毒治疗患者中,2451名(27%)因怀孕或母乳喂养(选项B+)状态而开始接受抗逆转录病毒治疗。多变量分析表明,年龄≥35岁且为女性与艾滋病毒治疗的抗逆转录病毒治疗前和治疗阶段失访风险降低相关。然而,处于世界卫生组织临床分期3期(调整风险比(aRR)1.35,95%置信区间(CI):1.20 - 1.51)和4期(aRR 1.87,95%CI:1.62 - 2.18)、开始抗逆转录病毒治疗时体重指数≤18.4(aRR 1.24,95%CI:1.11 - 1.39)、对门诊预约依从性差(aRR 4.55,95%CI:4.16 - 4.97)以及在农村机构接受艾滋病毒治疗(aRR 2.32,95%CI:1.94 - 2.87)与抗逆转录病毒治疗患者失访风险增加相关。曾重新开始抗逆转录病毒治疗一次(aRR 0.20,95%CI:0.17 - 0.22)、多次(aRR 0.06,95%CI:0.05 - 0.07)以及在患者数量少的机构登记(aRR 0.25,95%CI:0.20 - 0.30)与抗逆转录病毒治疗失访风险降低相关。

结论

相当一部分抗逆转录病毒治疗失访发生在怀孕或哺乳期登记的女性中。不遵守门诊预约以及在农村机构或患者数量多的机构接受抗逆转录病毒治疗与抗逆转录病毒治疗失访风险增加相关。制定针对高危亚组和环境的有效干预措施可能有助于减少艾滋病毒治疗中的失访。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验